NCT05725057

Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

A Phase 2a, Proof of Concept Study Evaluating the Safety and Tolerability of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Artax Biopharma Inc · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Proof of concept study to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis. Patients will be evaluated for a 28-day treatment period with either AX-158 or Placebo and then followed for an additional 30 days for safety.

Detailed description

This is a Phase 2a Proof of Concept randomized, double-blind, placebo-controlled study to investigate the safety and tolerability of AX-158 in patients with mild to moderate Psoriasis. Participants will be randomized 2:1 to receive AX-158 or Placebo. A total of 30 participants will be treated for 28 days and followed for an additional 30 days for safety.

Conditions

• Psoriasis
• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	AX-158	Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.
DRUG	Placebo	Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.

Timeline

• Start date: 2023-11-30
• Primary completion: 2024-09-04
• Completion: 2024-10-04
• First posted: 2023-02-13
• Last updated: 2025-10-03

Locations

6 sites across 1 country: United Kingdom